Search PubMed⌕ Search

Biomedical subjects

J Huber

Publications and source records attributed to J Huber.

At least 145 records · Page 8Linked to original sources
PubMed1993

[Type II multiple endocrine neoplasms (MEN IIB): an unusual cause of constipation. A plea for early thyroidectomy].

We present a 5 year old girl who was diagnosed to have multiple endocrine neoplasia syndrome type IIB (MEN IIB). She presented with serious constipation and had the distinct features of MEN IIB. 100% of the patients with MEN IIB develop medullary thyreoïd carcinoma (MTC). MTC in MEN IIB is known to behave in a very aggressive way. Microscopically MTC was already present in this patient despite of normal calcitonin stimulation tests. Accordingly we plead for a more radical management relating to thyreoïdectomy in MEN IIB.

Child, Preschool↗
PubMed1993

[Diagnosis and therapy of osteoporosis from the viewpoint of the gynecologist].

Osteoporosis can be prevented fairly effectively by the administration of estrogen and androgen. Therefore, a screening procedure is necessary to detect high-risk patients who may not have any subjective symptoms. The endocrine profile is also very valuable in this respect. Estrogens and androgens can be used in the first line for prophylaxis, but they should also be considered for the treatment of osteoporosis.

Adult↗
PubMed1992

[Bone density before and after the hormonal therapy of young women with hypergonadotropic hypogonadal amenorrhea].

Dual energy X-ray absorptiometry of bone density in the lumbar vertebral column was performed in 32 young women (mean age 24.6 [19-34] years) with hypergonadotropic hypogonadal amenorrhoea. There was a significantly lower bone density (0.74 +/- 0.27 g/cm2) than in a control group of 27 women of similar age (1.17 +/- 0.081 g/cm2; P less than 0.001). Subsequently 21 of the 32 women received cyclical hormone substitution therapy for 24 months (day 1-30: 0.625 mg conjugated oestrogens; additionally, on days 20-30: 5 mg medrogestone; followed by a seven-day pause). After 6 months bone density, compared with that of the 11 untreated women, had increased significantly (P less than 0.001). It is therefore recommended that young hypoestrogenemic women should receive early and continuous hormone substitution treatment.

Absorptiometry, Photon↗
PubMed1992

Influence of rheumatoid synovial fluid and cells on proteoglycans in human cartilage explants. Modulation by piroxicam.

We have studied the effects of cell-free rheumatoid synovial fluid (RASF) and the conditioned medium (CM) from these cells on the proteoglycans (PGs) of normal human cartilage and the influence which piroxicam might have on these processes. Both RASF and the CM from RASF cells enhanced the PG release from the cartilage explants. The effects of the above mentioned fluids on the cartilage PG content depended on the metabolic state of the cartilage i.e. correlated inversely with the PG synthesis. Whether this was due to the presence of anabolic and catabolic factors in these fluids is discussed. Piroxicam had no adverse effect on the PGs of human cartilage in vitro. Piroxicam prevented the cartilage PG depletion when it was induced by the CM from RASF cells.

Adult↗
PubMed1992

The neural and neuro-endocrine component of the human thymus. I. Nerve-like structures.

The presence of nerve-like fibers in the human thymus was studied by immunohistochemistry on frozen tissue sections and sections of formalin-fixed paraffin-embedded tissue, for neurofilaments (Nf) of 68-, 160-, and 200-kDa (neuron-specific structural proteins), neuron-specific protein PGP9.5, tyrosin hydroxylase (noradrenergic innervation), chromogranin A (CHROM), synaptophysin (SYN), and the pituitary hormones follicle-stimulating hormone (FSH) and its beta-subunit, growth hormone, adrenocorticotropic hormone, luteinizing hormone, prolactin, beta-subunit of thyroid-stimulating hormone, and somatostatin. Noradrenergic profile-like immunoreactivity was observed in the medulla: immunolabeling was observed also for epithelial cells surrounding Hassall's corpuscles. For neurofilaments, only Nf 160-kDa immunoreactivity was observed in the thymic parenchyma, mainly in long-sized labeling patterns in the medulla. PGP9.5 immunolabeling occurred especially in the cortex, in dendritic labeling patterns compatible with the epithelial network at this location. The medulla showed PGP9.5 immunoreactivity in fiber-like patterns and in large-sized epithelial cells surrounding Hassall's corpuscles. Immunoreactive CHROM was seen in profile-like structures in the subcapsule, cortex, and medulla. SYN immunolabeling occurred focally around Hassall's corpuscles. Profile-like structures immunoreactive for pituitary hormones were observed in the medulla and in less density in the cortex. For FSH the highest density occurred in the cortex, where long-sized profile-like structures were present running over and in between cells, especially in the keratin-positive epithelial dendritic network (two-color immunohistochemistry).

Adolescent↗
PubMed1992

The neural and neuro-endocrine component of the human thymus. II. Hormone immunoreactivity.

We evaluated the presence of anterior pituitary hormones; follicle-stimulating hormone (FSH) and its beta-subunit (beta-FSH), luteinizing hormone (LH) and its beta-subunit (beta-LH), beta-subunit of thyroid-stimulating hormone (beta-TSH), adrenocorticotropic hormone (ACTH), growth hormone (GH), and prolactin (PRL); the placental hormone human chorionic gonadotropin (hCG); and somatostatin, in paraffin and frozen sections of the human thymus. Epithelial cells in the medulla were immunoreactive for most of these hormones, in varying density and intensity of labeling. The cells labeled varied from epithelial cells surrounding Hassall's corpuscles toward solitary cells or small epithelial aggregates in the medulla. FSH immunoreactivity did occur predominantly in epithelial cells of the cortex, in apparent contrast to the predominant medullary location of cells immunolabeled for beta-FSH. The epithelial nature of FSH-immunoreactive cells was confirmed by two-color immunohistochemistry with anti-keratin antibody. In addition to FSH, some epithelial cells in subcapsule and cortex were labeled by antibodies to beta-FSH, beta-LH, beta-TSH, ACTH, GH, and PRL. Some macrophage-like cells surrounded by a rosette of lymphocytes were immunoreactive for FSH and GH. Some interdigitating reticulum-like cells were labeled by anti-beta-LH. Immunolabeling of lymphocytes was found for hCG, especially lymphocytes in the medulla. Two-color immunohistochemistry with anti-CD3 revealed a strong CD3 expression on hCG-immunoreactive cells, whereas CD3-negative cells were hCG-negative. T cells immunolabeled for hCG were also found in peripheral lymphoid organs.

Adolescent↗
PubMed1992

Hypergonadotropic hypogonadic amenorrhea (World Health Organization III) and osteoporosis.

OBJECTIVE: To assess the bone mineral density in World Health Organization (WHO) III women after hormone replacement therapy. DESIGN: We studied the bone mineral density of 41 women with premature ovarian failure (hypergonadotropic hypogonadic amenorrhea--WHO III) before and during hormone replacement therapy. SETTING: All WHO III women were recruited from the Outpatient Department of the First Department of Gynecology and Obstetrics, University of Vienna Medical School, Austria, a public University Hospital. PATIENTS, PARTICIPANTS: Forty-one patients, 30 healthy women. INTERVENTIONS: Twenty-eight of 41 WHO III women received cyclic hormone replacement therapy consisting of 0.625 mg conjugated estrogen (days 1 to 30) and 5 mg medrogeston (days 20 to 30) in addition, with a 7-day interval. MAIN OUTCOME MEASURE: The bone mineral density was evaluated by single photon absorptiometry and dual energy x ray absorptiometry every 6 months (single photon absorptiometry six times, dual energy x ray absorptiometry four times). RESULTS: The bone mineral density in young women with hypergonadotropic hypogonadic amenorrhea (WHO III) was lower than in age-matched controls. Hormone replacement therapy produced an increase in bone mineral density in 28 WHO III women, whereas bone mineral density remained quite constant in the women without therapy. CONCLUSION: Hormone replacement therapy increases the bone mineral density of women with hypergonadotropic hypogonadic amenorrhea. Hormones should be substituted early and consistently in affected patients.

Adult↗
PubMed1992

Physical map of the Cryptophlebia leucotreta granulosis virus genome and its relationship to the genome of Cydia pomonella granulosis virus.

A physical map of the genome of Cryptophlebia leucotreta granulosis virus (CIGV) was constructed for the restriction enzymes BamHI, EcoRI, KpnI, NdeI, NruI, SacI and XhoI using hybridization techniques. The size of the viral genome was determined to be 112.4 kbp. A restriction fragment library covering almost the entire genome of CIGV was constructed, and the position of the granulin gene was identified by cross-hybridization with granulin coding fragments of Cydia pomonella granulosis virus (CpGV). Two further regions of intergenomic similarity between CIGV and CpGV were mapped. These regions were aligned and show a collinear arrangement.

Baculoviridae↗
PubMed1992

Clinical experience with a new norgestimate-containing oral contraceptive.

Research in the area of oral contraception currently focuses on the development of selective progestogens that combine targeted progestational and antiovulatory activity with a minimal potential for androgenicity. The present dual-center study was conducted to investigate the efficacy, tolerability, and safety of a new monophasic oral contraceptive (OC) containing 250 micrograms norgestimate in combination with 35 micrograms ethinyl estradiol (Ortho-Cyclen or Cilest). Ninety-seven healthy women of childbearing age participated in the study: 37 received the new norgestimate/ethinyl estradiol combination OC as primary therapy and 31 were switched over from other OCs. The norgestimate/ethinyl estradiol formulation was well tolerated and was associated with excellent cycle control. After six cycles of use, there were no statistically significant differences in the incidence of spotting or breakthrough bleeding compared with baseline, nor were there any significant changes in the incidence of headache, nausea, or mastalgia. Body weights remained constant for the duration of the study, as did systolic and diastolic blood pressures. Of particular note was the absence of any statistically significant alterations in metabolic parameters, including blood glucose or lipoprotein levels. These findings are consistent with the results of several other European studies and indicate that the norgestimate/ethinyl estradiol combination OC combines superior cycle control with minimal risk of androgenic side effects.

Adult↗
PubMed1992

[Care for brothers and sisters of crib death children. Evaluation of a support project as an alternative to home monitoring].

A pilot-study was carried out on support measures chosen by 40 families having a subsequent child after their experience with a cot-death infant. Cardio-respiratory monitors were used in one group and weighing scales in the other. General support measures given to both groups included the keeping of symptom charts and weekly visits by health-nurses. Parents who used a home-monitor relied upon the medical-technical approach of the problem, while parents using scales were mainly given confidence by the personal attention of the health-nurse. Monitor-parents more often called the paediatrician for advice than parents using weighing-scales. Especially parents who used weighing-scales commented on the great value of the symptom diary and the weekly home-visit of the health-nurse.

Anxiety↗
PubMed1992

Pathology of congenital immunodeficiencies.

The histopathologic investigation of children with congenital immunodeficiency, and its relation to functional parameters and clinical data have been a major contribution to the present knowledge on the histophysiologic aspects of normal immune system function. Based on thorough knowledge in histophysiologic and dynamic aspects of lymphoid organs, the histopathologic evaluation in cases of suspected immunodeficiency today forms an integral part of the assessment of the immune status. Apart from conventional histologic techniques, advanced technology such as immunohistochemistry and in situ hybridization is applied. This enables analysis of the basic cellular components in various lymphoid tissue compartments, and evaluation of the consequences of the deficiency by the assessment of microorganisms and neoplasia. This review focuses on the histopathologic contribution to immunodeficiency evaluation. Sections deal with (1) the description of alterations in the various lymphoid tissues (bone marrow, thymus, lymph node, spleen, and gastrointestinal tissue); (2) histopathology of infection and malignancy; (3) pathology of some types of congenital immunodeficiency; (4) histopathologic methods and reagents; and (5) an autopsy protocol for immunodeficiency.

Child↗
PubMed1992

[A main symptom of the climacteric manifestation complex: arthropathia climacteria].

In the last few years several studies have been published raising the question whether hormonal factors are co-responsible for the female prevalence of certain joint diseases. From our own clinical experience we know that more than half of the women seen at our outpatients department because of disorders of the post menopausal syndrome complain about arthralgies (especially of the PIP-joints). We have introduced the term "arthropathia climacterica" for it. Moreover the positive results of two clinical studies on which effects hormone replacement therapy had on these complaints indicate a relation between estrogens and joints.

Arthritis, Rheumatoid↗
PubMed1992

[Differentiated therapy of the climacteric syndrome].

The replacement therapy is postmenopausal women is seen to be for transformation of the oestrogen-stimulated endometrium only, which does not apply to hysterectomised women. Because of the influence of estrane on lipids, one often advises against a replacement therapy with progestogens in hysterectomised women. With increasing knowledge of encountered extragenital functions of sexual steroids, the latter is questionable, if natural progesterone is given, which is (said to be) lipid-neutral, performing the function of the progestogens, which is quite more than reproduction only, more efficiently than estrane or gonane. Due to the competitive blocking of aldosterone the effect of progesterone is sodium-diuretic and diuretic, being as important as the therapy of climacteric complaints, as well as the consequence, which is the result of the physiological connection between progesterone and encephalics. Moreover, the effect of the progestogens is to tonicise the vascular system and is linked to a number of intestinal hormones in order to adjust their function. Therefore, progesterone seems to perform a great variety of extragenital functions. Menopausal women should not be deprived of the benefits of these functions within the framework of a replacement therapy.

Androgens↗